Table 1.
Patient demographic data, Montreal disease phenotype classification and medication exposure. Active inflammation defined as disease activity reported endoscopically or histologically. Other medications included sirolimus and abatacept.
| Number of individual patients | 20 |
|---|---|
| Biopsy samples, total | 42 |
| Collected at colonoscopy (%) | 34 (81) |
| Collected at bowel resection (%) | 8 (19) |
| Samples taken in presence of any active inflammation (% of samples) | 37 (88) |
| Endoscopic inflammation (% of samples) | 28 (67) |
| Histologic inflammation (% of those with result available, n = 36) | 30 (71) |
| Active inflammation at all time-points (% of patients) | 12 (60) |
| Active initially, remission at follow-up (% of patients) | 3 (15) |
| Disease in remission at all time-points (% of patients) | 0 (0) |
| Remission initially, active inflammation at follow-up (% of patients) | 4 (20) |
| Samples taken in disease remission (% of samples) | |
| Endoscopic remission (% of samples) | 14 (33) |
| Histologic remission (% of those with result available, n = 36) | 4 (10) |
| Age at time of procedure, years (SD) | 41 (11) |
| Active smoker at time of procedure (% of patients) | 6 (30) |
| Duration of disease since diagnosis, years (SD) | 13.6 (12.6) |
| Range (years) | 0–42 |
| Time between samples, mean years (SD) | 2.4 (1.7) |
| Range (years) | 0.5 – 5.9 |
| Number of patients with Crohn's disease (% of patients) | 16 (80) |
| Crohn's disease location classification (%) | |
| L1 (ileum only) | 4 (25) |
| L2 (colon only) | 2 (13) |
| L3 (ileum and colon) | 9 (56) |
| L4 (upper gastrointestinal tract) | 2 (13) |
| Crohn's disease phenotype classification (%) | |
| B1 (inflammatory) | 5 (31) |
| B2 (stricturing) | 9 (56) |
| B3 (penetrating) | 2 (13) |
| p (perianal involvement) | 5 (31) |
| Number of patients with ulcerative colitis (% of patients) | 4 (20) |
| Ulcerative colitis disease extent classification (%) | |
| E1 (distal) | 0 |
| E2 (left sided) | 1 (25%) |
| E3 (pan colitis) | 3 (75%) |
| Number of previous surgeries (% of samples) | |
| 0 | 26 (62) |
| 1 | 11 (26) |
| 2 | 1 (4) |
| 3 | 4 (10) |
| Medications being taken at time of procedure (% of samples) | |
| No medications | 12 (29) |
| Antibiotics | 3 (7) |
| Mesalazine | 4 (10) |
| Thiopurines | 15 (36) |
| Methotrexate | 2 (5) |
| Anti-TNFα | 10 (24) |
| Prednisone | 3 (7) |
| Other medications | 3 (35) |